OmniAb, Inc. (OABI)
NASDAQ: OABI · IEX Real-Time Price · USD
4.660
-0.020 (-0.43%)
At close: Jul 19, 2024, 4:00 PM
4.640
-0.020 (-0.43%)
Pre-market: Jul 22, 2024, 7:35 AM EDT
OmniAb Revenue
OmniAb had revenue of $21.05M in the twelve months ending March 31, 2024. Revenue in the quarter ending March 31, 2024 was $3.80M. In the year 2023, OmniAb had annual revenue of $34.16M.
Revenue (ttm)
$21.05M
Revenue Growth
-68.29%
P/S Ratio
25.93
Revenue / Employee
$198,547
Employees
106
Market Cap
545.81M USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 34.16M | -24.91M | -42.17% |
Dec 31, 2022 | 59.08M | 24.33M | 70.02% |
Dec 31, 2021 | 34.75M | 11.48M | 49.34% |
Dec 31, 2020 | 23.27M | 4.95M | 27.02% |
Dec 31, 2019 | 18.32M | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Cross Country Healthcare | 1.78B |
Castle Biosciences | 250.73M |
Canopy Growth | 218.49M |
Quanterix | 125.98M |
PureTech Health | 3.33M |
OABI News
- 6 weeks ago - OmniAb Announces Publication of Scientific Paper on Heavy Chain-Only Single-Domain Antibody Chicken Platform in the Journal of Immunology - Business Wire
- 2 months ago - OmniAb to Participate in the Jefferies Global Healthcare Conference - Business Wire
- 2 months ago - OmniAb Presents High-Throughput Single B-cell Screening xPloration® Data at the 20th Annual PEGS Boston Summit - Business Wire
- 2 months ago - OmniAb Reports First Quarter 2024 Financial Results and Business Highlights - Business Wire
- 2 months ago - OmniAb to Participate in Five Investor Conferences in May - Business Wire
- 3 months ago - OmniAb to Report First Quarter 2024 Financial Results on May 9 - Business Wire
- 3 months ago - Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics - Accesswire
- 4 months ago - OmniAb Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights - Business Wire